A Combination of Prebiotic Inulin and Oligofructose Improve Some of Cardiovascular Disease Risk Factors in Women with Type 2 Diabetes: A Randomized Controlled Clinical Trial.

Advanced pharmaceutical bulletin
Q1
Nov 2015
Citations:80
Influential Citations:3
Interventional (Human) Studies
87
S2 IconPDF Icon

Enhanced Details

Methods
Randomized, triple-blind, placebo-controlled trial; 70 women with type 2 diabetes, aged 20–65 years, BMI >25 kg/m^2; allocated to 10 g/day oligofructose-enriched inulin or maltodextrin placebo for 8 weeks; completed: 52 (27 in intervention, 25 in placebo).
Intervention
10 g/day oligofructose-enriched inulin for 8 weeks; taken as two 5 g portions with breakfast and dinner, with water.
Results
After 8 weeks, oligofructose-enriched inulin significantly improved several cardiovascular risk factors. Glycemic control improved: fasting plasma glucose decreased by 19.2 mg/dL (9.4%); HbA1c decreased by 0.5 percentage points. Lipid profile improved: total cholesterol decreased by 28.0 mg/dL (14.1%); LDL-C decreased by 22.0 mg/dL (21.7%); TC/HDL-C ratio decreased by 0.73 (20.7%); LDL-C/HDL-C ratio decreased by 0.55 (27.5%); MDA decreased by 1.7 nmol/mL (39.7%); TAC increased by 0.2 mmol/L (20%). Weight decreased from 76.0 ± 12.4 kg to 72.9 ± 12.4 kg and BMI from 31.9 ± 4.5 to 30.6 ± 4.6 kg/m^2. Triglycerides and HDL-C changes were not significant; SOD, GSH-Px and catalase changes were not significant between groups, though SOD and catalase rose within the intervention group. Effects remained after adjustment for diabetes duration, weight, and energy intake. No adverse effects were reported, and compliance was high. Conclusion: Oligofructose-enriched inulin may improve glycemic indices, lipid profile, antioxidant status, and oxidant stress marker (MDA) in women with type 2 diabetes, suggesting potential cardiovascular risk reduction.
Limitations
Short duration (8 weeks). Small sample size and participant attrition (70 randomized; 52 completed). Population limited to overweight women with type 2 diabetes in Iran; generalizability may be limited. Not assessed gut microbiota changes, serum fatty acids, glucose clamps, or other oxidative stress indices (e.g., F2-isoprostanes). Some outcomes may be underpowered; energy intake declined in the intervention group, which could confound results.

Abstract

PURPOSE This trial was conducted to evaluate the effects of oligofructose-enriched inulin on some of cardiovascular disease risk factors in women with type 2 diabetes. METHODS 52 females (25<BMI<35 kg/m2) with type 2 diabetes were randomly assigned...